Philip Philip

4.6k total citations
23 papers, 480 citations indexed

About

Philip Philip is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Philip Philip has authored 23 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Philip Philip's work include Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Philip Philip is often cited by papers focused on Pancreatic and Hepatic Oncology Research (7 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Philip Philip collaborates with scholars based in United States, Spain and United Kingdom. Philip Philip's co-authors include Andrew M. Lowy, Robert Marsh, Alan P. Venook, Mitchell C. Posner, Joseph M. Herman, Steven R. Alberts, Peter W. T. Pisters, Qian Shi, Jordan Berlin and Syed A. Ahmad and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and Cancer Research.

In The Last Decade

Philip Philip

21 papers receiving 476 citations

Peers

Philip Philip

ONCOL

PRM

SURGE

EPIDE

Laith Abushahin United States

Depei Huang China

Yingjie Shao China

Suebpong Tanasanvimon Thailand

Carol A. Sherman United States

Taro Hara Japan

Marta Soares Portugal

Simonetta Chiara Stani Italy

Andrea Lanese Italy

Jacob S. Ankeny United States

Laith Abushahin United States

Philip Philip

409 ×1.1

ONCOL

174 ×1.0

PRM

90 ×0.6

127 ×0.9

SURGE

75 ×0.9

EPIDE

Citations per year, relative to Philip Philip Philip Philip (= 1×) peers Laith Abushahin

Countries citing papers authored by Philip Philip

Since Specialization

Citations

This map shows the geographic impact of Philip Philip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Philip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Philip more than expected).

Fields of papers citing papers by Philip Philip

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Philip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Philip. The network helps show where Philip Philip may publish in the future.

Co-authorship network of co-authors of Philip Philip

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Philip. A scholar is included among the top collaborators of Philip Philip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Philip. Philip Philip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hijaz, Miriana, Radhika Gogoi, Philip Philip, et al.. (2024). Deciphering the metabolic regulation of immunosuppressive CD11b+Gr1+ myeloid cells in epithelial ovarian cancer.. The Journal of Immunology. 212(1_Supplement). 0266_4898–0266_4898.

Eng, Cathy, Emerson Y. Chen, Jane E. Rogers, et al.. (2021). Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice. 17(10). 607–614. 6 indexed citations

Lou, Emil, Joanne Xiu, Yasmine Baca, et al.. (2021). Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS. Cells. 10(6). 1275–1275. 8 indexed citations

Hall, William A., Husain Yar Khan, Mandana Kamgar, et al.. (2021). Abstract PO-024: Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. Cancer Research. 81(22_Supplement). PO–24. 1 indexed citations

Naylor, Paul H., et al.. (2019). Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center. Journal of Gastrointestinal Cancer. 51(3). 972–979. 2 indexed citations

Fernández-Zapico, Martín E., Dae Won Kim, Philip Philip, et al.. (2019). Abstract B15: Therapeutic potential of targeting amino acid metabolism in pancreatic cancer. Cancer Research. 79(24_Supplement). B15–B15. 2 indexed citations

Javle, Milind, Robin Kate Kelley, Sameek Roychowdhury, et al.. (2019). AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions. HepatoBiliary Surgery and Nutrition. 8(S1). AB051–AB051. 16 indexed citations

Picozzi, Vincent J., Vaibhav Sahai, Diane M. Simeone, et al.. (2017). A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer. Annals of Oncology. 28. iii81–iii82. 1 indexed citations

Salem, Mohamed E., Heinz‐Josef Lenz, Anthony F. Shields, et al.. (2017). Molecular variations between small bowel adenocarcinomas (SBAs), right-sided colon cancers (RT-Colon), and gastroesophageal cancers (GEC). Annals of Oncology. 28. iii143–iii144. 2 indexed citations

10.

Lenz, Heinz‐Josef, Philip Philip, Mark Saunders, et al.. (2017). Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 80(6). 1161–1169. 7 indexed citations

11.

Hammel, Pascal, Jill Lacy, Fabienne Portales, et al.. (2016). P-272 The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC). Annals of Oncology. 27. ii78–ii78. 1 indexed citations

12.

Sahai, Vaibhav, et al.. (2016). P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study. Annals of Oncology. 27. ii83–ii83. 4 indexed citations

13.

Diab, Maria, Irfana Muqbil, Ramzi M. Mohammad, Asfar S. Azmi, & Philip Philip. (2016). The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Journal of Clinical Medicine. 5(6). 59–59. 27 indexed citations

14.

Shaikh, Talha, Mark Zaki, M.M. Dominello, et al.. (2015). Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer. Acta Oncologica. 55(3). 303–308. 10 indexed citations

15.

Tempero, Margaret A., Dana B. Cardin, Andrew V. Biankin, et al.. (2015). Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT). Gastroenterology. 148(4). S–944. 1 indexed citations

16.

Philip, Philip, et al.. (2014). Conventional risk factors for myocardial infarction in the Maltese population - results from the Maltese Acute Myocardial Infarction (MAMI) study. International Journal of Pharmaceutics. 529(1-2). 1–14.

17.

Konski, André, Joshua E. Meyer, Michael C. Joiner, et al.. (2014). Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiotherapy and Oncology. 113(1). 35–40. 11 indexed citations

18.

Sethi, Seema, et al.. (2014). Abstract 5589: Molecular diagnostic, prognostic and therapeutic role of mir-221 in pancreatic cancer. Cancer Research. 74(19_Supplement). 5589–5589. 1 indexed citations

19.

Katz, Matthew H. G., Robert Marsh, Joseph M. Herman, et al.. (2013). Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design. Annals of Surgical Oncology. 20(8). 2787–2795. 245 indexed citations

20.

Merati, Kambiz, Mir S. Siadaty, Aleodor A. Andea, et al.. (2001). Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and Its Relationship to Pathologic and Clinical Parameters. American Journal of Clinical Oncology. 24(5). 447–452. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact